Contrasting Mazor Robotics (MZOR) and Boston Scientific Corporation (BSX)
Mazor Robotics (NASDAQ: MZOR) and Boston Scientific Corporation (NYSE:BSX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.
Insider & Institutional Ownership
28.4% of Mazor Robotics shares are held by institutional investors. Comparatively, 92.1% of Boston Scientific Corporation shares are held by institutional investors. 0.7% of Boston Scientific Corporation shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk and Volatility
Mazor Robotics has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. Comparatively, Boston Scientific Corporation has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.
Earnings and Valuation
This table compares Mazor Robotics and Boston Scientific Corporation’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Mazor Robotics||$48.85 million||18.20||-$18.28 million||($0.79)||-46.67|
|Boston Scientific Corporation||$8.71 billion||4.16||$2.31 billion||$0.58||45.54|
Boston Scientific Corporation has higher revenue and earnings than Mazor Robotics. Mazor Robotics is trading at a lower price-to-earnings ratio than Boston Scientific Corporation, indicating that it is currently the more affordable of the two stocks.
This table compares Mazor Robotics and Boston Scientific Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Boston Scientific Corporation||9.04%||23.62%||9.01%|
This is a summary of current recommendations and price targets for Mazor Robotics and Boston Scientific Corporation, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Boston Scientific Corporation||0||4||13||0||2.76|
Mazor Robotics currently has a consensus price target of $35.00, indicating a potential downside of 5.07%. Boston Scientific Corporation has a consensus price target of $30.39, indicating a potential upside of 15.08%. Given Boston Scientific Corporation’s stronger consensus rating and higher probable upside, analysts clearly believe Boston Scientific Corporation is more favorable than Mazor Robotics.
Boston Scientific Corporation beats Mazor Robotics on 12 of the 13 factors compared between the two stocks.
About Mazor Robotics
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications. Its Renaissance System and its predecessor are used in a number of spine surgeries, including fusion, correction of spinal deformities, biopsy collection, tumor excision and cement augmentations. Furthermore the Company developed the Renaissance Brain Module, an application of its Renaissance System that provides control over the insertion of surgical instruments during brain surgery.
About Boston Scientific Corporation
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.
Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.